An Outbreak of ST80 Vancomycin-Resistant Enterococcus faecium in a Hospital in Guangzhou, China: Clinical and Genomic Epidemiology Study from 2022 to 2023.

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES
Yawen Deng, Xiaoying Xie, Baiji Chen, Zhixan Zhang, Jiaoni Lan, Yi Luan, Guanhua Rao, Peng Han, Chaohui Duan
{"title":"An Outbreak of ST80 Vancomycin-Resistant <i>Enterococcus faecium</i> in a Hospital in Guangzhou, China: Clinical and Genomic Epidemiology Study from 2022 to 2023.","authors":"Yawen Deng, Xiaoying Xie, Baiji Chen, Zhixan Zhang, Jiaoni Lan, Yi Luan, Guanhua Rao, Peng Han, Chaohui Duan","doi":"10.1177/10766294251361345","DOIUrl":null,"url":null,"abstract":"<p><p>A notable increase in the incidence of vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) was observed at a hospital in Guangzhou, China, during 2022-2023. We conducted a retrospective cross-sectional study from January 1, 2022, to August 31, 2023, to investigate the clinical and genomic characteristics of VREfm. Clinical data were extracted from electronic medical records, and infection control measures were reviewed from the relevant department. VREfm confirmation was performed using antimicrobial susceptibility testing. Genomic characteristics were analyzed via the whole-genome sequencing. The prevalence of VREfm among <i>E. faecium</i> isolates rose significantly from 13.3% (10/75) in 2022 to 26.4% (40/151) by August 2023 (<i>p</i> < 0.001). Concurrently, usage of third-generation cephalosporins increased by 8.4% (22.47 to 24.36 defined daily doses per 100 patient days), carbapenems by 34% (51.47-68.97), and vancomycin by 18% (21.15-24.97) (all <i>p</i> ≤ 0.001). Molecular analysis revealed ST80/CC17 (78%, 39/50) as the dominant clone, carrying <i>vanA</i> and virulence genes (<i>scm</i>, <i>acm,</i> and <i>fss3</i>), suggesting clonal expansion of a lineage rarely reported in Guangzhou. Our study documented an outbreak of ST80/CC17 <i>vanA</i>-positive VREfm, characterized by virulence genes (<i>scm</i>, <i>acm,</i> and <i>fss3</i>) and clonal dominance (78%, 39/50). The temporal association between reduced sodium hypochlorite disinfection (2.7-fold decline, <i>p</i> = 0.002), increased antibiotic selective pressure, and pathogen transmission highlights multifactorial drivers of this epidemic. These findings underscore the complex multifactorial nature of pathogen transmission, including the role of antibiotic use, infection control measures, and environmental factors in the spread of multidrug-resistant clones. Strengthened infection control strategies-integrating targeted disinfection, antibiotic stewardship, and genomic surveillance-are imperative to curb the spread of such multidrug-resistant clones.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10766294251361345","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

A notable increase in the incidence of vancomycin-resistant Enterococcus faecium (VREfm) was observed at a hospital in Guangzhou, China, during 2022-2023. We conducted a retrospective cross-sectional study from January 1, 2022, to August 31, 2023, to investigate the clinical and genomic characteristics of VREfm. Clinical data were extracted from electronic medical records, and infection control measures were reviewed from the relevant department. VREfm confirmation was performed using antimicrobial susceptibility testing. Genomic characteristics were analyzed via the whole-genome sequencing. The prevalence of VREfm among E. faecium isolates rose significantly from 13.3% (10/75) in 2022 to 26.4% (40/151) by August 2023 (p < 0.001). Concurrently, usage of third-generation cephalosporins increased by 8.4% (22.47 to 24.36 defined daily doses per 100 patient days), carbapenems by 34% (51.47-68.97), and vancomycin by 18% (21.15-24.97) (all p ≤ 0.001). Molecular analysis revealed ST80/CC17 (78%, 39/50) as the dominant clone, carrying vanA and virulence genes (scm, acm, and fss3), suggesting clonal expansion of a lineage rarely reported in Guangzhou. Our study documented an outbreak of ST80/CC17 vanA-positive VREfm, characterized by virulence genes (scm, acm, and fss3) and clonal dominance (78%, 39/50). The temporal association between reduced sodium hypochlorite disinfection (2.7-fold decline, p = 0.002), increased antibiotic selective pressure, and pathogen transmission highlights multifactorial drivers of this epidemic. These findings underscore the complex multifactorial nature of pathogen transmission, including the role of antibiotic use, infection control measures, and environmental factors in the spread of multidrug-resistant clones. Strengthened infection control strategies-integrating targeted disinfection, antibiotic stewardship, and genomic surveillance-are imperative to curb the spread of such multidrug-resistant clones.

广州某医院ST80耐万古霉素屎肠球菌暴发:2022 - 2023年临床与基因组流行病学研究
在2022-2023年期间,中国广州一家医院观察到耐万古霉素屎肠球菌(VREfm)的发病率显著增加。我们从2022年1月1日至2023年8月31日进行了一项回顾性横断面研究,以调查VREfm的临床和基因组特征。从电子病历中提取临床资料,并从相关部门审核感染控制措施。采用抗菌药敏试验进行VREfm确认。通过全基因组测序分析基因组特征。从2022年的13.3%(10/75)上升到2023年8月的26.4%(40/151),差异有统计学意义(p < 0.001)。同时,第三代头孢菌素的使用量增加了8.4%(每100患者日定义剂量22.47 ~ 24.36),碳青霉烯类增加了34%(51.47 ~ 68.97),万古霉素增加了18%(21.15 ~ 24.97)(均p≤0.001)。分子分析显示ST80/CC17(78%, 39/50)为优势克隆,携带vanA和毒力基因(scm, acm和fss3),提示广州罕见的谱系克隆扩增。我们的研究记录了ST80/CC17钒-阳性VREfm的爆发,其特征是毒力基因(scm、acm和fss3)和克隆优势(78%,39/50)。次氯酸钠消毒减少(下降2.7倍,p = 0.002)、抗生素选择压力增加和病原体传播之间的时间相关性突出了这种流行病的多因素驱动因素。这些发现强调了病原体传播的复杂多因素性质,包括抗生素使用、感染控制措施和环境因素在耐多药克隆传播中的作用。加强感染控制策略——整合有针对性的消毒、抗生素管理和基因组监测——对于遏制这种多药耐药克隆的传播至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Microbial drug resistance
Microbial drug resistance 医学-传染病学
CiteScore
6.00
自引率
3.80%
发文量
118
审稿时长
6-12 weeks
期刊介绍: Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信